Breadcrumb

Asset Publisher

null Genomic and Pharmacogenomic

Description

The Genomics and Pharmacogenomics Group focuses its efforts on three interrelated objectives in infectious diseases, specifically on HIV and its clinical management to adress a translational perspective:

  • To investigate host genetics identifying drug combination most likely to be tolerated and effective. The possibility to develop predictive tools to reduce toxicities and adverse effects due to antirretroviral treatment (ART), including dyslipidaemia, atherosclerosis and cardiovascular disease, lipodystrophy and hypersensitivity reactions. 
  • To explain inter-individual differences in susceptibility and response to pathogens. Genomic and transcriptomic approaches in extreme cases of HIV disease progression, as elite controllers, is rellevant for understanding pathogenesis and for therapeutic vaccine development.
  • To discover new therapeutic targets associated to lipid metabolism and host lipid membrane composition. In vitro and in vivo approaches on macrophages and CD4 reservoirs to study the cholesterol metabolism and fatty acid composition altered by HIV infection.

Close collaboration between this group and Hospital dia Infeccioses (Hospital Clínic Barcelona) and Red de Investigación SIDA de España (RIS) allow the possibility to combine basic and applied research. The group also carries out collaborative projects with a number of teams both nationally and internationally, receiving funding from both the public and private sector for specific projects, participates in the training of junior researchers and prioritizes the diffusion of scientific advances via medical journals, congresses, conferences, courses and books.

Related Assets

Members

Mireia Arnedo
Tuixent Escriba
Roque Pastor
Olivia Tort

Related Assets

Related Assets

Publications

  • ω-3 supplementation in HIV-1-infected individuals with unsuppressed viral load: cause for caution? 
    Tort O, Sánchez-Palomino S, Escribà T, Calvo C, González T, Gatell JM, Sala-Vila A, Arnedo M.  AIDS. 2016 Nov 13;30(17):2733-2735. 
  • HIV Controllers Consortium of the AIDS Spanish Network. MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression 
    Egaña-Gorroño L, Guardo AC, Bargalló ME, Planet E, Vilaplana E, Escribà T, Pérez I, Gatell JM, García F, Arnedo M*, Plana M M;  PLoS One. 2016 May 12;11(5):e0155245. 
  • Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. 
    Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Miralles C, Domingo P, Montero M, del Rio L, Fontdevila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E.  HIV Med. 2016 May;17(5):340-9. 
  • Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. 
    León A, Leal L, Torres B, Lucero C, Inciarte A, Arnedo M, Plana M, Vila J, Gatell JM, García F.  AIDS. 2015 Mar 27;29(6):675-81 
  • Differential Subcutaneous Adipose Tissue Gene Expression Pattern with Efavirenz or Lopinavir/ritonavir in Antiretroviral-Naïve Patients: A Randomized Clinical Trial. 
    Egaña-Gorroño L, Martínez E, Domingo P, Loncà M, Escribà T, Fontdevila J, Vidal F, Negredo E, Gatell JM, Arnedo M.  Antimicrob Agents Chemother. 2014 
  • Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults. 
    Egaña-Gorroño L, Martínez E, Pérez I, Escribà T, Domingo P, Gatell JM, Arnedo M.  J Antimicrob Chemother. 2014 
  • HIV Controllers Consortium of the AIDS Spanish Network. Differential MicroRNA Expression Profile between Stimulated PBMCs from HIV-1 Infected Elite Controllers and Viremic Progressors. 
    Egaña-Gorroño L, Escribà T, Boulanger N, Guardo AC, León A, Bargalló ME, Garcia F, Gatell JM, Plana M, Arnedo M;  PLoS One. 2014 Sep 16;9(9):e106360. 
  • Non-AIDS, AIDS events and death in a cohort de antiretroviral naïve HIV-infected patients with a CD4 T cell count above 500 cells/mm3. 
    Constanza Lucero, Berta Torres, Agathe León, Marta Calvo, Lorna Leal, Iñaki Pérez, Montserrat Plana, Mireia Arnedo, Josep Mallolas, Josep M Gatell, Felipe García.  AIDS Res Hum Retroviruses. 2013 ;8:1161-7. 
  • Contribution of genetic background, traditional risk factors and HIV-related factors to coronary artery disease events in HIV-positive persons. 
    M Rotger et al for the MAGNIFICENT Consortium†, INSIGHT‡ and the Swiss HIV Cohort Study.  Clin Infect Dis. 2013;1:112-21. 
  • Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy. 
    Lander Egaña-Gorroño, Esteban Martínez, Bru Cormand, Tuixent Escribà, Jose Gatell, Mireia Arnedo.  AIDS, 2013, vol 27:529-38. 

Related Assets

Network